false
0001544227
0001544227
2026-11-12
2026-11-12
0001544227
TPST:CommonStock0.001ParValueMember
2026-11-12
2026-11-12
0001544227
TPST:SeriesJuniorParticipatingPreferredPurchaseRightsMember
2026-11-12
2026-11-12
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
November 12, 2026
Tempest Therapeutics, Inc.
(Exact name of Registrant as Specified in Its
Charter)
| Delaware |
|
001-35890 |
|
45-1472564 |
|
(State or Other Jurisdiction
of Incorporation) |
|
(Commission File Number) |
|
(IRS Employer
Identification No.) |
| 2000 Sierra Point Parkway, Suite 400 |
|
|
| Brisbane, California |
|
94005 |
| (Address of Principal Executive Offices) |
|
(Zip Code) |
Registrant’s Telephone Number, Including
Area Code: (415) 798-8589
(Former Name or Former Address, if Changed Since
Last Report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☒ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b)
of the Act:
| Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
| Common Stock, $0.001 par value |
|
TPST |
|
The Nasdaq Stock Market LLC |
| Series A Junior Participating Preferred Purchase Rights |
|
N/A |
|
The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act. ☐
Item 5.07. Submission of Matters to
a Vote of Security Holders.
The information disclosed in Item 8.01 of this
Current Report on Form 8-K is incorporated herein by reference.
Item 8.01. Other Events.
On November 12, 2026, Tempest Therapeutics, Inc.
(the “Company”) called to order its reconvened special meeting of stockholders (the “Special Meeting”) originally
convened and adjourned on July 27, 2026. The Special Meeting had previously been reconvened and adjourned on August 17, 2026, September
15, 2026 and October 14, 2026. The purpose of the Special Meeting is to approve a Certificate of Amendment to the Company’s Restated
Certificate of Incorporation to replace specified supermajority voting requirements and permit stockholder action by written consent in
the form attached as Exhibit A to the proxy statement previously distributed to the Company’s stockholders in connection with the
Special Meeting (the “Proposal”).
At the Special Meeting, a total of 11,052,422
shares, or 74.64% of the 14,806,997 shares of common stock outstanding as of May 28, 2026, the record date for the Special Meeting, were
present virtually or represented by proxy, constituting a quorum. However, because there were not sufficient votes to approve the Proposal
at the time of the Special Meeting, the Company decided to adjourn the Special Meeting to provide stockholders with additional time to
vote and to facilitate broader participation.
The Special Meeting will reconvene on December
11, 2026 at 12:00 p.m. Eastern Time via live webcast at the following virtual meeting link, www.virtualshareholdermeeting.com/TPST2026SM2.
Stockholders can use the same access code to attend the reconvened meeting on December 11, 2026 that was used for the originally scheduled
Special Meeting convened on July 27, 2026.
The Proposal requires the affirmative vote of
the holders of at least seventy-five percent (75%) of the votes that all the stockholders would be entitled to cast in any annual election
of directors or class of directors.
No changes have been made to the Proposal to be
voted on by the stockholders at the Special Meeting. The record date for determining stockholder eligibility to vote at the Special Meeting
remains the close of business on May 28, 2026. Proxies previously submitted will be voted at the reconvened Special Meeting unless properly
revoked, and stockholders who have already submitted a proxy or otherwise voted and do not wish to change their vote need not take any
action.
Important Additional Information and Where to Find It:
The Company has filed a definitive proxy statement
and other relevant documents with the U.S. Securities and Exchange Commission (“SEC”) in connection with the Special Meeting.
INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE DEFINITIVE PROXY STATEMENT AND OTHER RELEVANT DOCUMENTS FILED WITH THE SEC CAREFULLY
AND IN THEIR ENTIRETY because they contain important information about the matters to be voted on at the Special Meeting. Stockholders
may obtain copies of these documents free of charge at the SEC’s website at www.sec.gov or on the Company’s website at https://www.tempesttx.com.
Participants in the Solicitation:
The Company and its directors and executive officers
may be deemed to be participants in the solicitation of proxies from the Company’s stockholders in connection with the Special Meeting.
Information about the Company’s directors and executive officers and about their ownership of the Company’s common stock is
outlined in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 30, 2026,
as updated by the definitive proxy statement for the 2026 Annual Meeting of Stockholders, which was filed with the SEC on October 26,
2026 and the Company’s Current Report on Form 8-K filed with the SEC on October 30, 2026. The Company has also engaged Sodali &
Co., a proxy solicitation firm, to assist with obtaining adequate votes to achieve the required quorum of a majority of the outstanding
shares of the Company’s common stock entitled to vote at the Special Meeting.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| |
TEMPEST THERAPEUTICS, INC. |
| |
|
|
| Date: November 16, 2026 |
By: |
/s/ Matthew Angel |
| |
Name: |
Matthew Angel |
| |
Title: |
President and Chief Executive Officer |